Sarepta Therapeutics, Inc. $SRPT Shares Bought by Nordea Investment Management AB

Nordea Investment Management AB raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 69,363 shares of the biotechnology company’s stock after acquiring an additional 1,066 shares during the quarter. Nordea Investment Management AB’s holdings in Sarepta Therapeutics were worth $1,185,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of SRPT. Ancora Advisors LLC boosted its position in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $44,000. Pandora Wealth Inc. acquired a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $45,000. Brooklyn Investment Group increased its position in Sarepta Therapeutics by 450.4% during the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares in the last quarter. Finally, Blue Trust Inc. increased its position in Sarepta Therapeutics by 542.3% during the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,771 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on SRPT shares. Piper Sandler increased their price objective on shares of Sarepta Therapeutics to $15.00 and gave the company a “neutral” rating in a research report on Tuesday, July 29th. Sanford C. Bernstein started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They issued a “market perform” rating and a $13.00 price objective for the company. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, July 28th. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Jefferies Financial Group decreased their price target on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, July 24th. Eight analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have issued a Sell rating to the company. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average price target of $34.46.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $21.89 on Friday. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The firm has a fifty day moving average of $19.88 and a 200-day moving average of $28.49. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -25.16 and a beta of 0.51.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. During the same period in the previous year, the business earned $0.07 earnings per share. The company’s revenue was up 68.4% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.